fresh knowledge of genetic biomarke...

fresh knowledge of genetic biomarkers for disease is spurring progress to maturity of pharmacogenomic (PG)-based drugs and biological fruits and raising new challenges for FDA and manufacturers. Genomics information promises to goad discovery of more individualized treatment regimens by means of identifying patients most likely to accord to certain medicines--as well as individuals more susceptible to adverse affairs
Manufacturers can use this information to excellent high-response individuals for clinical trials, an approach that promises to abridge clinical research costs, accelerate medicine ...